Drug research

IMU-838

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as IM90838; Vidofludimus calcium; vidofludimus calcium

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Phase 2 Dose-finding IMU-838 for Ulcerative ColitisNCT03341962	Immunic AG	Phase 2	Terminated	2022-11-16Actual
A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)NCT04379271	Immunic AG	Phase 2, Phase 3	Completed	2021-01-12Actual
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple SclerosisNCT05054140	Immunic AG	Phase 2	Unknown	2025-01-07Estimated

Immunic AGTerminatedPrimary completion: 2022-11-16 · Actual

Trial details

Immunic AGCompletedPrimary completion: 2021-01-12 · Actual

Trial details

Immunic AGUnknownPrimary completion: 2025-01-07 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.